Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
197
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,142.00 | 63.40 | -0.69% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,451.98 | 669.42 | -1.34% |
| FTSE 100 | 10,402.44 | 69.67 | -0.67% |
| HKSE | 26,523.07 | 509.47 | -1.88% |
| NASDAQ | 22,597.15 | 469.32 | -2.03% |
| Nikkei 225 | 57,268.49 | 371.35 | -0.64% |
| NZX 50 Index | 13,198.18 | 333.30 | -2.46% |
| S&P 500 | 6,832.76 | 108.71 | -1.57% |
| S&P/ASX 200 | 8,920.40 | 52.50 | -0.59% |
| SSE Composite Index | 4,109.19 | 24.82 | -0.60% |